ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a research note released on Thursday morning,Benzinga reports. They currently have a $30.00 price target on the stock.

A number of other research firms have also commented on IBRX. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd. Piper Sandler decreased their price target on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday, August 19th.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX traded down $0.06 during mid-day trading on Thursday, reaching $5.04. 3,139,928 shares of the company traded hands, compared to its average volume of 4,958,448. The company's fifty day moving average is $4.27 and its two-hundred day moving average is $5.15. ImmunityBio has a fifty-two week low of $3.10 and a fifty-two week high of $10.53. The stock has a market cap of $3.51 billion, a PE ratio of -5.54 and a beta of 0.99.

Institutional Trading of ImmunityBio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of ImmunityBio by 1.6% in the first quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company's stock valued at $72,708,000 after buying an additional 211,065 shares during the period. Axxcess Wealth Management LLC acquired a new position in ImmunityBio in the 1st quarter valued at approximately $85,000. Lazard Asset Management LLC grew its holdings in shares of ImmunityBio by 102.6% during the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company's stock worth $68,000 after purchasing an additional 6,593 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of ImmunityBio by 3.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company's stock worth $667,000 after purchasing an additional 4,533 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of ImmunityBio during the first quarter valued at approximately $499,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.